CN119137262A - 经改造细胞及使用方法 - Google Patents

经改造细胞及使用方法 Download PDF

Info

Publication number
CN119137262A
CN119137262A CN202380037757.5A CN202380037757A CN119137262A CN 119137262 A CN119137262 A CN 119137262A CN 202380037757 A CN202380037757 A CN 202380037757A CN 119137262 A CN119137262 A CN 119137262A
Authority
CN
China
Prior art keywords
cell
cells
protein
nucleic acid
transgene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380037757.5A
Other languages
English (en)
Chinese (zh)
Inventor
盖伊·M·克鲁克斯
唐纳德·B·科恩
桑·皮尔·柳
帕特里克·常
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN119137262A publication Critical patent/CN119137262A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202380037757.5A 2022-03-02 2023-03-02 经改造细胞及使用方法 Pending CN119137262A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263315579P 2022-03-02 2022-03-02
US202263315581P 2022-03-02 2022-03-02
US63/315,581 2022-03-02
US63/315,579 2022-03-02
US202363442966P 2023-02-02 2023-02-02
US63/442,966 2023-02-02
PCT/US2023/063587 WO2023168341A1 (en) 2022-03-02 2023-03-02 Engineered cells and methods of use

Publications (1)

Publication Number Publication Date
CN119137262A true CN119137262A (zh) 2024-12-13

Family

ID=87884252

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380037757.5A Pending CN119137262A (zh) 2022-03-02 2023-03-02 经改造细胞及使用方法

Country Status (6)

Country Link
EP (1) EP4486870A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025507864A (cg-RX-API-DMAC10.html)
CN (1) CN119137262A (cg-RX-API-DMAC10.html)
AU (1) AU2023227880A1 (cg-RX-API-DMAC10.html)
CA (1) CA3253740A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023168341A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117030580B (zh) * 2023-09-15 2024-07-16 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) LDNs在坏死性小肠结肠炎诊断中的应用
WO2026123001A2 (en) * 2024-12-06 2026-06-11 Umoja Biopharma, Inc. Lineage-loci engineered cell therapy and related methods of producing and using same
WO2026133125A1 (en) * 2024-12-16 2026-06-25 Janssen Biotech, Inc. T cell-specific promoters and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716570A4 (en) * 1993-09-03 1997-12-17 Systemix Inc Genetically Modified Human Hematopoietic Stem Cells and Their Offspring
AU2018301667A1 (en) * 2017-07-12 2020-02-06 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Foundation Methods and systems for conditionally regulating gene expression
EP4171616A1 (en) * 2020-06-26 2023-05-03 Juno Therapeutics GmbH Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods

Also Published As

Publication number Publication date
WO2023168341A1 (en) 2023-09-07
EP4486870A1 (en) 2025-01-08
CA3253740A1 (en) 2023-09-07
AU2023227880A1 (en) 2024-10-17
JP2025507864A (ja) 2025-03-21
EP4486870A4 (en) 2026-05-20

Similar Documents

Publication Publication Date Title
JP7402211B2 (ja) 幹細胞からt細胞を作製する方法および該t細胞を用いた免疫療法的方法
AU2019287483B2 (en) Stem cell-engineered iNKT cell-based off-the-shelf cellular therapy
AU2023227880A1 (en) Engineered cells and methods of use
TW202122575A (zh) 工程化的t細胞及其產生方法
WO2024102707A1 (en) Methods and compositions for generating immune cells from progenitor cells
WO2025208050A2 (en) Engineered mucosal-associated invariant t (mait) cells and methods of making and using thereof
EP4735581A2 (en) Methods of making and using engineered immune cells
EP4526429A2 (en) Engineered cells and methods of use
EP4665845A1 (en) Pluripotent stem cell-engineered immune cells for off-the-shelf cell therapy
BR112018008648B1 (pt) Método para a preparação de uma composição de células t a partir de células tronco ou progenitoras e seus usos
EA048607B1 (ru) Способы получения т-клеток из стволовых клеток и иммунотерапевтические способы применения т-клеток

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination